| 1 |
Lipton A. New therapeutic agents for the treatment of bone diseases. Expert Opin Biol Ther. 2005; 5: 817-32.
DOI
ScienceOn
|
| 2 |
Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol. 2007; 5: 475-82.
|
| 3 |
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61:1115-7.
DOI
ScienceOn
|
| 4 |
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009; 67(5 Suppl):2-12.
DOI
ScienceOn
|
| 5 |
Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, Nakayama T, Bessho K. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg. 2012; 41:1397-403.
DOI
ScienceOn
|
| 6 |
Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144:753-61.
DOI
ScienceOn
|
| 7 |
Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993; 14: 690-709.
|
| 8 |
Frolik CA, Black EC, Cain RL, Satterwhite JH, Brown-Augsburger PL, Sato M, Hock JM. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone. 2003; 33: 372-9.
DOI
ScienceOn
|
| 9 |
Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab. 2004; 15: 60-5.
DOI
ScienceOn
|
| 10 |
Lee JJ, Cheng SJ, Jeng JH, Chiang CP, Lau HP, Kok SH. Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck. 2011; 33: 1366-71.
DOI
ScienceOn
|
| 11 |
Kwon YD, Lee DW, Choi BJ, Lee JW, Kim DY. Shortterm teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int. 2012; 23: 2721-5.
DOI
ScienceOn
|
| 12 |
Narvaez J, Narvaez JA, Gomez-Vaquero C, Nolla JM. Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw. Osteoporos Int. 2013; 24: 731-3.
DOI
ScienceOn
|
webmaster
